KPIs & Operating Metrics(New)
Breakdown Of AssetsCollaboration Revenue BreakdownCollaboration Revenue Breakdown AnnualContractual ObligatonsCost Of SalesDeferred RevenueEmployee StatisticsGross Margin %Gross ProfitIncome (Loss) Before Provision For Income TaxNon Gaap ExpensesNon Gaap Expenses AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of Total Revenue %OPEX SegregationProduct Revenue Breakdown AnnualProperty And Equipment, Net BreakdownRevenue By ProductRevenue By Product %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Total Pmo Product Revenues, Net BreakdownTotal Pmo Product Revenues, Net Breakdown Annual
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Gross Profit: 2012-2025

Historic Gross Profit for Sarepta Therapeutics (SRPT) over the last 11 years, with Jun 2025 value amounting to $473.5 million.

  • Sarepta Therapeutics' Gross Profit rose 48.73% to $473.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.5 billion, marking a year-over-year increase of 11.92%. This contributed to the annual value of $1.6 billion for FY2024, which is 44.82% up from last year.
  • Per Sarepta Therapeutics' latest filing, its Gross Profit stood at $473.5 million for Q2 2025, which was up 322.79% from $112.0 million recorded in Q1 2025.
  • In the past 5 years, Sarepta Therapeutics' Gross Profit ranged from a high of $526.1 million in Q4 2024 and a low of $112.0 million during Q1 2025.
  • Moreover, its 3-year median value for Gross Profit was $335.5 million (2023), whereas its average is $326.1 million.
  • In the last 5 years, Sarepta Therapeutics' Gross Profit soared by 66.10% in 2024 and then plummeted by 69.14% in 2025.
  • Sarepta Therapeutics' Gross Profit (Quarterly) stood at $169.7 million in 2021, then spiked by 34.12% to $227.6 million in 2022, then surged by 54.90% to $352.6 million in 2023, then spiked by 49.21% to $526.1 million in 2024, then soared by 48.73% to $473.5 million in 2025.
  • Its Gross Profit was $473.5 million in Q2 2025, compared to $112.0 million in Q1 2025 and $526.1 million in Q4 2024.